3Lappe JM, Pelfrey CM,Tang WH. Recent insights into the role of autoim- munity in idiopathic dilated cardiomyopathy E J]-J Card Fail,2008,14: 521 - 530.
6Kubanek M ,Sramko M, Maluskova J, et al. Novel predictors of left ventricular reverse remodeling in individuals with recent-onset dilat- ed cardiomyopathy [ J ]. J Am Coll Cardiol,2013,61 ( 1 ) :54 - 63.
7Kim H,Shin HW, Son J, et al. Uric Acid as prognostic marker in advanced nonischemic dilated cardiomyopathy: comparison with N- terminal pro B - type natriuretic peptide level [ J ]. Congest Heart Fail,2010,16(4) :153 - 158.
8Tigen K,Cevik C. Beta-blockers in the treatment of dilated cardio- myopathy:which is the best? [J]. Curr Pharm Des, 2010, 16 (26) :2866 - 2871.
9Peter S, Macdonald PS. Heart failure with preserved ejection frac- tion-coming to terms with an oxymoron [ J ]. The Medical journal of Australia,2010,192 ( 1 ) :4 - 5.
10Zuber M,Cuculi F,Atlenhofer Jost CH,et al. Value of brain natri- urctic peptides in primary care patients with the clinical diagnosis of chronic heart failure [ J ]. Scandinavian cardiovascular journal: SCJ, 2009,43 ( 5 ) :324 - 329.
